生物医药全产业链数据服务平台
企业版官网
掌上数据
打开微信扫一扫
数据开放平台
产品矩阵
摩熵数科产品矩阵
查看详情
{{ item.category }}
{{ product.info.desc }}
-
{{ listItem.name }}快速筛选药品，用摩熵药筛
微信扫一扫-立即使用
个人版
企业版
高校版
摩熵咨询
咨询服务
-
产品立项评估及管线规划
-
数据定制服务
-
产业/行业调研
-
市场洞察咨询服务
资源大厅
-
报告大厅
已收录 68518 份 -
摩熵说直播
最新改良型新药及创新药立项开发
请输入关键词
历史搜索
热门搜索
- GLP-1
投融资数据库
免费查数据
注册送3天会员
首页>投融资
Enterome
未透露
Enterome is a privately owned stratified medicine company dedicated to the development of drugs and biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine.In June 2020, the company announced a new financing totaling EUR 46.3 million (US $52.6million) to progress the clinical development of its therapeutic pipeline and closed a Series E round with new investors including SymBiosis and Takeda Pharmaceutical.In January 2018, the company raised EUR 32 million (US $38.5 million) in a series D financing round, and secured a EUR 40 million (US $48 million) loan facility from the European Investment Bank. In June 2020, the company made first drawdown from the loan .In April 2016, the company raised EUR 14.5 million (US $16.44 million) in a Series C financing round. Nestle Health Science invested alongside with existing investors.In May 2014, Enterome raised EUR 10 million (US $13.83 million) from the first
基本信息
-
公司全称ENTEROME SA
-
类型免疫调节药物研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址94/96 avenue Ledru-Rollin PARIS ILE-DE-FRANCE 75011; FR; Telephone: +33175772785;
-
联系电话33 1 76 2158 19
-
邮箱belichard@enterome.com
-
成立时间2012-01-01
投融资
-
2023-10-30未公开300万欧元Therapy Acceleration Program
-
2023-10-30未透露300万欧元The Leukemia & Lymphoma Society Therapy Acceleration Program
-
2020-06-25E轮4630万欧元Omnes CapitalPrincipia SGRTakedaSeventure PartnersNestlé Health ScienceHealth for Life Capital fundSymbiosis
-
2020-06-25E~PreIPO4630万欧元Omnes CapitalHealth for Life Capital fundSeventure PartnersTakedaNestlé Health ScienceSymbiosisPrincipia SGR
-
2018-01-04D轮3200万欧元Bristol-Myers SquibbOmnes CapitalLundbeckfonden VenturesSeventure PartnersNestlé Health ScienceHealth for Life Capital fundEuropean Investment Bank （EIB）Principia SGR
-
2018-01-04债权融资4000万欧元Omnes CapitalHealth for Life Capital fundSeventure Partners百时美施贵宝European Investment Bank （EIB）Lundbeckfonden VenturesNestlé Health SciencePrincipia SGR
-
2017-01-01D轮3170万欧元Bristol-Myers SquibbOmnes CapitalLundbeckfonden VenturesSeventure PartnersNestlé Health ScienceHealth for Life Capital fundPrincipia SGR
-
2017-01-01D轮3170万欧元Omnes CapitalHealth for Life Capital fundSeventure Partners百时美施贵宝Lundbeckfonden VenturesNestlé Health SciencePrincipia SGR
-
2016-04-20C轮1450万欧元Omnes CapitalLundbeckfonden VenturesSeventure PartnersHealth for Life Capital fundNestlé Health Science
-
2016-04-20C轮1450万欧元Omnes CapitalHealth for Life Capital fundSeventure PartnersLundbeckfonden VenturesNestlé Health Science
-
2014-05-05B轮1000万欧元Omnes CapitalSeventure PartnersLundbeckfonden Ventures
-
2014-05-01B轮1000万欧元Seventure PartnersOmnes CapitalLundbeckfonden Ventures
-
2012-03-23A轮500万欧元Seventure PartnersOmnes CapitalLundbeckfonden VenturesShire
-
2012-03-23A轮750万欧元Seventure PartnersOmnes CapitalLundbeckfonden VenturesShire
-
2012-03-23A轮750万欧元Omnes CapitalSeventure PartnersShireLundbeckfonden Ventures
-
2011-01-01种子轮150万欧元未透露
-
2011-01-01种子轮150万欧元Seventure Partners
- 加载更多
相关投融资企业
A轮
柏全生物是一家肿瘤免疫新靶点发现整合平台，基于创始团队在肿瘤免疫领域独到而深刻的见解，公司搭建了肿瘤免疫新靶点发现的整合平台——BioTroy Engine，并通过临床蛋白质组学与受体组学等系统性研究，充分验证了新靶点可独立介导肿瘤免疫逃逸的功能与相应的转化医学开发价值。同时，公司构建了极高的专利壁垒，从多个层面对新靶点进行了保护，并完成了靶点生物学、抗体发现、CMC小试工艺平台的建设。
C轮
PolyActiva Pty Ltd, formed as a joint venture between CSIRO and the Bionic Ear Institute, became operationally independent in January 2011. The company focuses on the development of drug-polymer conjugates that enable site specific drug delivery from medical device components, such as implants, films or fibres.In July 2019, the company had closed an AU$10 million(US$7 million) capital raised.In February 2013, the company raised AUD $9.2 Million (US $ 9,522,460) from a series B financing round.By July 2011, the company had received AUD $2.4 million (US $2.58 million) from the Medical Research Commercialisation Fund
天使轮
杭州景嘉航生物医药科技有限公司是一家新型靶向放射性药物研发商，处于临床研究阶段的创新药公司，聚焦新型的靶向放射性药物的研发，以满足未满足的临床需求，为肿瘤患者提供更多的选择。
添加收藏
新建收藏夹
取消
确认
摩熵数据
药品研发
全球上市
药品销售
市场信息
一致性评价
原料药
生产检验
中药
专题数据库
摩熵医学
摩熵专利
摩熵原料药
摩熵投融资
摩熵生物
摩熵医械
数据服务
数据开放平台
购买咨询
18983288589（微信同号）
商务合作
18983288589（微信同号）
售后服务
18908392210（微信同号）
投诉建议
18980413049
关注tyc7111cc太阳成集团公众号
随时查阅行业资讯
tyc7111cc太阳成集团数据小程序
掌上数据查询系统
《互联网药品信息服务资格证》 证书号：（浙）-经营性-2021-0028
ICP备案号：蜀ICP备2021004927号-4
浙公网安备33011002015279
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: tyc7111cc太阳成集团 tyc7111cc太阳成集团企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网